Flo-pred is a drug owned by Taro Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2013. Out of these, 1 drug patents are active and 5 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 11, 2028. Details of Flo-pred's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7799331 | Oral suspension of prednisolone acetate |
Oct, 2028
(3 years from now) | Active |
| US6656482 | Spill resistant pharmaceutical system |
Jun, 2018
(6 years ago) |
Expired
|
| US6399079 | Spill resistant pharmaceutical compositions in semi-solid form |
Jun, 2018
(6 years ago) |
Expired
|
| US6071523 | Spill resistant pharmaceutical compositions in semi-solid form |
Jun, 2018
(6 years ago) |
Expired
|
| US5881926 | Pharmaceutical compositions in semisolid form and a device for administration thereof |
Mar, 2016
(8 years ago) |
Expired
|
| US6102254 | Pharmaceutical compositions in semisolid form and a device for administration thereof |
Mar, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Flo-pred's patents.
Latest Legal Activities on Flo-pred's Patents
Given below is the list of recent legal activities going on the following patents of Flo-pred.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Mar, 2022 | US7799331 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2018 | US7799331 |
| Email Notification Critical | 09 Mar, 2017 | US7799331 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Mar, 2017 | US7799331 |
| Correspondence Address Change Critical | 07 Mar, 2017 | US7799331 |
| Expire Patent Critical | 24 Dec, 2015 | US6656482 |
| Post Issue Communication - Certificate of Correction | 07 Dec, 2010 | US7799331 |
| Recordation of Patent Grant Mailed Critical | 21 Sep, 2010 | US7799331 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Sep, 2010 | US7799331 |
| Email Notification Critical | 02 Sep, 2010 | US7799331 |
US patents provide insights into the exclusivity only within the United States, but Flo-pred is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Flo-pred's family patents as well as insights into ongoing legal events on those patents.
Flo-pred's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Flo-pred's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 11, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Flo-pred Generic API suppliers:
Prednisolone Acetate is the generic name for the brand Flo-pred. 5 different companies have already filed for the generic of Flo-pred, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Flo-pred's generic
Alternative Brands for Flo-pred
Flo-pred which is used for treating allergic reactions and managing asthma symptoms., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Organon Llc |
| |||
About Flo-pred
Flo-Pred is a drug owned by Taro Pharmaceuticals Inc. It is used for treating allergic reactions and managing asthma symptoms. Flo-Pred uses Prednisolone Acetate as an active ingredient. Flo-Pred was launched by Taro in 2008.
Approval Date:
Flo-pred was approved by FDA for market use on 17 January, 2008.
Active Ingredient:
Flo-pred uses Prednisolone Acetate as the active ingredient. Check out other Drugs and Companies using Prednisolone Acetate ingredient
Treatment:
Flo-pred is used for treating allergic reactions and managing asthma symptoms.
Dosage:
Flo-pred is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 15MG BASE/5ML | SUSPENSION | Discontinued | ORAL |
| EQ 5MG BASE/5ML | SUSPENSION | Discontinued | ORAL |